ES2176329T3 - Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos. - Google Patents

Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos.

Info

Publication number
ES2176329T3
ES2176329T3 ES95918278T ES95918278T ES2176329T3 ES 2176329 T3 ES2176329 T3 ES 2176329T3 ES 95918278 T ES95918278 T ES 95918278T ES 95918278 T ES95918278 T ES 95918278T ES 2176329 T3 ES2176329 T3 ES 2176329T3
Authority
ES
Spain
Prior art keywords
antihistaminic
anhydrate
piperidine
derivatives
pseudomorphes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918278T
Other languages
English (en)
Inventor
Daniel R Henton
Frederick J Mccarty
Susan I Tripp
Jill E Dewitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176329(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2176329T3 publication Critical patent/ES2176329T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS PROCESOS PARA PREPARAR FORMAS ANHIDRAS E HIDRATOS DE DERIVADOS DE PIPERIDINA, POLIMORFOS Y PSUDOMORFOS DE LOS MISMOS DE FORMULAS (I) Y (II) QUE SON UTILES COMO ANTIHISTAMINICOS, AGENTES ANTIALERGICOS Y BRONCODILATADORES.
ES95918278T 1994-05-18 1995-04-28 Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos. Expired - Lifetime ES2176329T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11

Publications (1)

Publication Number Publication Date
ES2176329T3 true ES2176329T3 (es) 2002-12-01

Family

ID=26937420

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95918278T Expired - Lifetime ES2176329T3 (es) 1994-05-18 1995-04-28 Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos.

Country Status (17)

Country Link
US (12) US20010012896A1 (es)
EP (3) EP2354125A1 (es)
JP (7) JPH10500134A (es)
CN (3) CN1623985A (es)
AT (1) ATE220667T1 (es)
AU (1) AU693892B2 (es)
CA (3) CA2189007C (es)
DE (1) DE69527429T2 (es)
DK (1) DK0766668T3 (es)
ES (1) ES2176329T3 (es)
FI (1) FI964565A0 (es)
HU (1) HU227676B1 (es)
IL (3) IL134917A (es)
MX (1) MX9605613A (es)
NO (1) NO315319B1 (es)
PT (1) PT766668E (es)
WO (1) WO1995031437A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
CN1623985A (zh) * 1994-05-18 2005-06-08 阿温蒂斯药物公司 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
IN191492B (es) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
MXPA03009259A (es) * 2001-04-09 2004-06-03 Teva Pharma Polimorfos de clorhidrato de fexofenadina.
US7700779B2 (en) 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
BR0117054A (pt) * 2001-06-18 2004-07-27 Reddys Lab Ltd Dr Formas cristalinas do ácido 4-[4-[4-hidroxidifenilmetil)-1-piperidinil]-1-hidroxibuti l]-alfa, alfa-dimetilbenzeno acético e seu cloridrato
ATE389405T1 (de) * 2001-07-31 2008-04-15 Texcontor Ets Fexofenadine hydrochlorid polymorph
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
WO2003104197A1 (en) * 2002-06-10 2003-12-18 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
ES2322592T3 (es) * 2003-07-03 2009-06-23 Teva Pharmaceutical Industries Ltd. Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion.
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (en) * 2004-06-15 2006-02-08 Dipharma S.p.A. A process for the preparation of keto compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
EP1685106A2 (en) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadine crystal form and processes for its preparation thereof
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2011054741A2 (en) 2009-11-06 2011-05-12 Basf Se Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides
WO2011158262A1 (en) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation
IT1400965B1 (it) 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
BE794598A (fr) 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US3965257A (en) 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (es) 1991-04-08 1993-01-11 Green Cross Corp
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
JP3686950B2 (ja) 1992-04-10 2005-08-24 メレル ファーマスーティカルズ インコーポレイテッド ピペリジン誘導体類の新規な方法
NZ251834A (en) * 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
RU2167657C2 (ru) 1992-08-03 2001-05-27 Сепракор, Инк. Фармацевтическая композиция для лечения аллергических заболеваний, способ антигистаминного лечения, применение композиции для получения лекарственного препарата
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
CA2181089C (en) 1993-06-24 2000-05-23 Thomas E. D'ambra Piperidine derivatives and process for their production
DK1026147T3 (da) 1993-06-24 2004-03-22 Albany Molecular Res Inc Forbindelser, der er anvendelige som mellemprodukter i fremstillingen af piperidinderivater
CA2362337C (en) 1993-06-25 2005-08-02 Merrell Pharmaceuticals Inc. Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
CN1623985A (zh) * 1994-05-18 2005-06-08 阿温蒂斯药物公司 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法
US5576610A (en) 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
IL134771A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
US5574045A (en) 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
EP0998272B1 (en) 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
MXPA03009259A (es) * 2001-04-09 2004-06-03 Teva Pharma Polimorfos de clorhidrato de fexofenadina.
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Also Published As

Publication number Publication date
JP2002316978A (ja) 2002-10-31
US20080167471A1 (en) 2008-07-10
HUT76134A (en) 1997-06-30
CN1623985A (zh) 2005-06-08
CN1148849A (zh) 1997-04-30
US20010014741A1 (en) 2001-08-16
US7138524B2 (en) 2006-11-21
US7666881B2 (en) 2010-02-23
JP2010120969A (ja) 2010-06-03
DE69527429T2 (de) 2003-03-20
US20020193603A1 (en) 2002-12-19
EP0766668B1 (en) 2002-07-17
PT766668E (pt) 2002-11-29
FI964565L (fi) 1996-11-14
US20040014976A1 (en) 2004-01-22
DE69527429D1 (de) 2002-08-22
EP1178041A1 (en) 2002-02-06
EP2354125A1 (en) 2011-08-10
JP2002308849A (ja) 2002-10-23
CA2189007C (en) 2004-03-02
IL134917A0 (en) 2001-05-20
JP4503907B2 (ja) 2010-07-14
JP4503909B2 (ja) 2010-07-14
HK1098467A1 (en) 2007-07-20
NO964859L (no) 1996-11-15
US20080167469A1 (en) 2008-07-10
JP2002255936A (ja) 2002-09-11
EP0766668A1 (en) 1997-04-09
CA2585705C (en) 2012-04-17
CA2189007A1 (en) 1995-11-23
US7662835B2 (en) 2010-02-16
CA2585705A1 (en) 1995-11-23
AU693892B2 (en) 1998-07-09
US20010012896A1 (en) 2001-08-09
JP4503908B2 (ja) 2010-07-14
US20010025106A1 (en) 2001-09-27
US20070021461A1 (en) 2007-01-25
IL113747A (en) 2001-05-20
US20030045721A1 (en) 2003-03-06
HK1137742A1 (en) 2010-08-06
CA2449419A1 (en) 1995-11-23
CN1907967A (zh) 2007-02-07
FI964565A7 (fi) 1996-11-14
ATE220667T1 (de) 2002-08-15
US20070021462A1 (en) 2007-01-25
JPH10500134A (ja) 1998-01-06
JP2002308850A (ja) 2002-10-23
IL113747A0 (en) 1995-08-31
NO964859D0 (no) 1996-11-15
AU2426595A (en) 1995-12-05
MX9605613A (es) 1998-05-31
HU9603167D0 (en) 1997-01-28
US7135571B2 (en) 2006-11-14
DK0766668T3 (da) 2002-10-28
JP2002255935A (ja) 2002-09-11
IL134917A (en) 2001-07-24
WO1995031437A1 (en) 1995-11-23
CN1907967B (zh) 2012-07-04
CA2449419C (en) 2011-09-06
FI964565A0 (fi) 1996-11-14
US20020193600A1 (en) 2002-12-19
NO315319B1 (no) 2003-08-18
US20020193601A1 (en) 2002-12-19
HU227676B1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
MX9605613A (es) Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
AR003955A1 (es) Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen.
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
AR006390A1 (es) Derivados de lactama
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2141559T3 (es) Derivados de 2-ciano-1-sulfonamidofenil-1,3-diona y su uso como herbicidas.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2168737T3 (es) Inhibidores de la oxido nitrico sintasa.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2119203T3 (es) Derivados de poliamina n-alquiltio utilizados como agentes radioprotectores.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY24010A1 (es) Nuevos pirrolocarbazoles
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
SV1995000012A (es) Acidos 5-vinil- y 5-etinil-quinolon- y-naftiridon-carboxilicos,ref. lea 30239-sv.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2179864T3 (es) 4-benzoil-isoxazoles y su uso como herbicidas.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
ES2093286T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
MX9708510A (es) Tetralinas.